Effect of proton-pump inhibitor treatment on symptoms and quality of life in GERD patients depends on the symptom-reflux association

Journal of Clinical Gastroenterology

Volumn 42, Issue 5, 2008, Pages 441-447

  Aanen, Marissa C ^a   Weusten, Bas L A M ^b   Numans, Mattijs E ^a   De Wit, Niek J ^a   Samsom, Melvin ^a   Smout, André J P M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

Esomeprazole; Gastroesophageal reflux disease; Primary care; Proton pump inhibitor; Quality of life; Symptom reflux association

Indexed keywords

ACID; ESOMEPRAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSPEPSIA; ESOPHAGUS PH; EXPOSURE; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PH MEASUREMENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SENSITIVITY ANALYSIS; SHORT COURSE THERAPY; SYMPTOM; TREATMENT DURATION;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL PH MONITORING; FEMALE; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMP INHIBITORS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 42449089039     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318074dd62     Document Type: Article

References (40)

1. Rothman M, Farup C, Stewart W, et al. Symptoms associated with gastroesophageal reflux disease: development of a questionnaire for use in clinical trials. Dig Dis Sci. 2001;46:1540-1549.
2. Irvine EJ. Quality of life assessment in gastro-oesophageal reflux disease. Gut. 2004;53(suppl 4):35-39.
3. Wiklund I. Review of the quality of life and burden of illness in gastroesophageal reflux disease. Dig Dis. 2004;22:108-114.
4. Bytzer P. Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients. Am J Gastroenterol. 2003;98(suppl 3):S31-S39.
5. Chey WD, Inadomi JM, Booher AM, et al. Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol. 2005;100:1237-1242.
6. van Pinxteren B, Numans ME, Lau J, et al. Short-term treatment of gastroesophageal reflux disease. J Gen Intern Med. 2003;18:755-763.
7. Jones R, Galmiche JP. Review: what do we mean by GERD? - definition and diagnosis. Aliment Pharmacol Ther. 2005;22(suppl 1):2-10.
8. Bredenoord AJ, Weusten BL, Smout AJ. Symptom association analysis in ambulatory gastro-oesophageal reflux monitoring. Gut. 2005;54:1810-1817.
9. Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease-current concepts and dilemmas. Am J Gastroenterol. 2001;96:303-314.
10. Johnsson F, Weywadt L, Solhaug JH, et al. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol. 1998;33:15-20.
11. Kulig M, Leodolter A, Vieth M, et al. Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease - an analysis based on the ProGERD initiative. Aliment Pharmacol Ther. 2003;18:767-776.
12. 2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2006;3:CD002095.
13. Talley NJ, Fullerton S, Junghard O, et al. Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol. 2001;96:1998-2004.
14. Borgaonkar MR, Irvine EJ. Quality of life measurement in gastrointestinal and liver disorders. Gut. 2000;47:444-454.
15. Wiklund IK, Junghard O, Grace E, et al. Quality of Life in Reflux and Dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl. 1998;583:41-49.
16. Weusten BL, Roelofs JM, Akkermans LM, et al. The symptom-association probability: an improved method for symptom analysis of 24-hour esophageal pH data. Gastroenterology. 1994;107:1741-1745.
17. Ward BW, Wu WC, Richter JE, et al. Ambulatory 24-hour esophageal pH monitoring. Technology searching for a clinical application. J Clin Gastroenterol. 1986;8(suppl 1):59-67.
18. Breumelhof R, Smout AJ. The symptom sensitivity index: a valuable additional parameter in 24-hour esophageal pH recording. Am J Gastroenterol. 1991;86:160-164.
19. Clason DL, Dormody TJ. Analyzing data measured by individual Likert-type items. J Agricult Edu. 1994;35:31-35.
20. Whitley E, Ball J. Statistics review 6: nonparametric methods. Crit Care. 2002;6:509-513.
21. Bate CM, Green JR, Axon AT, et al. Omeprazole is more effective than cimetidine in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis. Aliment Pharmacol Ther. 1998;12:41-47.
22. Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther. 1997;11:765-773.
23. Johnsson F, Hatlebakk JG, Klintenberg AC, et al. Symptom-relieving effect of esomeprazole 40mg daily in patients with heartburn. Scand J Gastroenterol. 2003;38:347-353.
24. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol. 1998;10:119-124.
25. Orlando RC. The pathogenesis of gastroesophageal reflux disease: the relationship between epithelial defense, dysmotility, and acid exposure. Am J Gastroenterol. 1997;92(4 suppl):3S-5S.
26. Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy. A multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006;55:1398-1402.
27. Taghavi SA, Ghasedi M, Saberi-Firoozi M, et al. Symptom association probability and symptom sensitivity index: preferable but still suboptimal predictors of response to high dose omeprazole. Gut. 2005;54:1067-1071.
28. Bredenoord AJ, Weusten BL, Timmer R, et al. Addition of esophageal impedance monitoring to pH monitoring increases the yield of symptom association analysis in patients off PPI therapy. Am J Gastroenterol. 2006;101:453-459.
29. Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology. 2001;120:1599-1606.
30. Kennedy TM, Jones RH, Hungin AP, et al. Irritable bowel syndrome, gastro-oesophageal reflux, and bronchial hyper-responsiveness in the general population. Gut. 1998;43:770-774.
31. Talley NJ. A unifying hypothesis for the functional gastrointestinal disorders: really multiple diseases or one irritable gut? Rev Gastroenterol Disord. 2006;6:72-78.
32. Bradley LA, Richter JE, Pulliam TJ, et al. The relationship between stress and symptoms of gastroesophageal reflux: the influence of psychological factors. Am J Gastroenterol. 1993;88:11-19.
33. Wright CE, Ebrecht M, Mitchell R, et al. The effect of psychological stress on symptom severity and perception in patients with gastrooesophageal reflux. J Psychosom Res. 2005;59:415-424.
34. Pace F, Bollani S, Molteni P, et al. Natural history of gastrooesophageal reflux disease without oesophagitis (NERD) - a reappraisal 10 years on. Dig Liver Dis. 2004;36:111-115.
35. Isolauri J, Luostarinen M, Isolauri E, et al. Natural course of gastroesophageal reflux disease: 17 to 22 year follow-up of 60 patients. Am J Gastroenterol. 1997;92:37-41.
36. Fass R, Shapiro M, Dekel R, et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next? Aliment Pharmacol Ther. 2005;22:79-94.
37. Talley NJ, Armstrong D, Junghard O, et al. Predictors of treatment response in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2006;24:371-376.
38. Khajanchee YS, Hong D, Hansen PD, et al. Outcomes of antireflux surgery in patients with normal preoperative 24-hour pH test results. Am J Surg. 2004;187:599-603.
39. Thibault R, Coron E, Sebille V, et al. Antireflux surgery for non-erosive and erosive reflux disease in community practice. Aliment Pharmacol Ther. 2006;24:621-632.
40. Fass R, Tougas G. Functional heartburn: the stimulus, the pain, and the brain. Gut. 2002;51:885-892.